ImmuCell (NASDAQ:ICCC) Stock Price Passes Above Two Hundred Day Moving Average of $5.01

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.01 and traded as high as $5.31. ImmuCell shares last traded at $5.29, with a volume of 2,308 shares traded.

ImmuCell Trading Up 0.8 %

The company has a debt-to-equity ratio of 0.42, a current ratio of 2.73 and a quick ratio of 0.87. The company has a market capitalization of $41.39 million, a price-to-earnings ratio of -7.05 and a beta of 0.60. The business’s 50-day moving average price is $5.15 and its two-hundred day moving average price is $5.01.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.15) EPS for the quarter. The company had revenue of $5.10 million for the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ImmuCell stock. Mesirow Financial Investment Management Inc. bought a new stake in ImmuCell Co. (NASDAQ:ICCC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.